Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruiting
NCT05770037Phase 2, Phase 3Updated Nov 24, 2025
Sponsor: Cancer Research UK
Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type
United Kingdom
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Completed
NCT03193190Phase 1, Phase 2Updated Nov 21, 2025
Sponsor: Hoffmann-La Roche
Pancreatic Adenocarcinoma
United States, Germany, Japan, South Korea, Spain
A Study to Investigate Vamikibart in Participants With Uveitic Macular EdemaCompleted
NCT05642312Phase 3Updated Nov 21, 2025
Sponsor: Hoffmann-La Roche
Uveitic Macular Edema
United States, Austria, Brazil, Canada, China +9 more
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminated
NCT05954143Phase 2Updated Nov 20, 2025
Sponsor: Bolt Biotherapeutics, Inc.
Metastatic Breast Cancer · HER2-positive Breast Cancer
United States, Spain
Newborn Screening for Spinal Muscular AtrophyCompleted
NCT05481164N/AUpdated Nov 20, 2025
Sponsor: University of Oxford
Muscular Atrophy, Spinal
United Kingdom
Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabCompleted
NCT02433522Phase 3Updated Nov 20, 2025
Sponsor: Assistance Publique - Hôpitaux de Paris
ANCA-associated Vasculitides
France
Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase AntibodiesCompleted
NCT03385668Phase 2Updated Nov 20, 2025
Sponsor: Assistance Publique - Hôpitaux de Paris
Pulmonary Fibrosis
France
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompleted
NCT03498521Phase 2Updated Nov 19, 2025
Sponsor: Hoffmann-La Roche
Cancer of Unknown Primary Site
Australia, Austria, Brazil, Bulgaria, Chile +28 more
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical CystectomyActive Not Recruiting
NCT03697850Phase 2Updated Nov 18, 2025
Sponsor: UNICANCER
Bladder Cancer
France
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerRecruiting
NCT04624399Phase 2Updated Nov 18, 2025
Sponsor: Queen Mary University of London
Urogenital Cancer
United Kingdom
Identifying and Characterizing Preclinical MSRecruiting
NCT05787795N/AUpdated Nov 14, 2025
Sponsor: Yale University
Multiple Sclerosis
United States
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)Completed
NCT03599245Phase 3Updated Nov 12, 2025
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
Argentina, Belgium, Brazil, Bulgaria, Canada +21 more
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerCompleted
NCT03371017Phase 3Updated Nov 12, 2025
Sponsor: Hoffmann-La Roche
Triple Negative Breast Neoplasms
United States, Argentina, Bosnia and Herzegovina, Brazil, Chile +23 more
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompleted
NCT03280563Phase 1, Phase 2Updated Nov 10, 2025
Sponsor: Hoffmann-La Roche
Breast Neoplasms
United States, Israel, South Korea
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaCompleted
NCT02242942Phase 3Updated Nov 6, 2025
Sponsor: Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
United States, Argentina, Australia, Austria, Brazil +16 more
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationCompleted
NCT04777201Phase 3Updated Oct 24, 2025
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
United States, Argentina, Australia, Austria, Brazil +22 more
Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical PracticeTerminated
NCT05694013Phase 2, Phase 3Updated Oct 22, 2025
Sponsor: Hoffmann-La Roche
Cancer
Australia, Austria, Germany, Spain, Switzerland
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular EdemaCompleted
NCT05151744Phase 2Updated Oct 16, 2025
Sponsor: Hoffmann-La Roche
Diabetic Macular Edema
United States, Argentina, Canada, Israel, Poland +4 more
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerCompleted
NCT05945927N/AUpdated Oct 10, 2025
Sponsor: Hoffmann-La Roche
Breast Cancer
China
PRE-DETERMINE Cohort StudyActive Not Recruiting
NCT01114269N/AUpdated Oct 7, 2025
Sponsor: Brigham and Women's Hospital
Coronary Artery Disease · Left Ventricular Dysfunction · Sudden Cardiac Death
United States, Canada, Puerto Rico
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC PatientsRecruiting
NCT05377034Phase 2Updated Oct 6, 2025
Sponsor: National Cancer Centre, Singapore
Locally Advanced Hepatocellular Carcinoma
China, Singapore, South Korea, Taiwan
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular AtrophyCompleted
NCT03032172Phase 2Updated Oct 1, 2025
Sponsor: Hoffmann-La Roche
Spinal Muscular Atrophy
United States, Belgium, France, Germany, Italy +4 more
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)Recruiting
NCT04111978Phase 3Updated Sep 29, 2025
Sponsor: Swiss GO Trial Group
Ovarian Neoplasm Epithelial · Fallopian Tube Neoplasms · Peritoneal Neoplasms · High-grade Serous Ovarian Carcinoma (HGSOC)
Austria, Germany, Switzerland
PRecision Oncology Evidence Development in Cancer Treatment - LiquidActive Not Recruiting
NCT05057234NAUpdated Sep 25, 2025
Sponsor: British Columbia Cancer Agency
Cancer
Canada
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCCompleted
NCT03041311Phase 2Updated Sep 25, 2025
Sponsor: G1 Therapeutics, Inc.
Small Cell Lung Cancer
United States, Bulgaria, Estonia, France, Latvia +2 more

Previous page Next page